Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TOP Trial. A Randomised Phase III Clinical Trial of Trastuzumab (Herceptin) Optimization in Patients With Locally Advanced and/or Metastatic Breast Cancer Overexpressing HER2 After a First Line Chemotherapy Plus Trastuzumab.

NCT00637325 is registered in ClinicalTrials.gov with Regione Lombardia as lead sponsor.

NCT NCT00637325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00637325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TOP Trial. A Randomised Phase III Clinical Trial of Trastuzumab (Herceptin) Optimization in Patients With Locally Advanced and/or Metastatic Breast Cancer Overexpressing HER2 After a First Line Chemotherapy Plus Trastuzumab.
Lead sponsor
Regione Lombardia
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2007
Completion date
April 30, 2011
Enrollment
500 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or locally advanced breast cancer